PHOTOS: Venus, Mars, Jupiter, & the Moon seen from Hillsville
For those who may have missed the action, there was a lunar occultation of Saturn when the moon passed in front of the planet, Jupiter ended retrograde motion, the Planetary Alignment during which the visible planets, including Mercury, Venus, Mars, Jupiter, Saturn, Uranus, and Neptune appeared in a 'string' across the sky, and a Full Snow Moon.
PHOTOS: Full Wolf Moon, Mars in Hillsville & more
During that time, a local stargazer, Jean from Hillsville submitted some stellar photos of the night sky. Check them out below and remember, if you have images or videos of something happening near you, submit them to our WFXR 'Report It Page' and they may just make it online or on air.
Thank you Jean from Hillsville!
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
2 hours ago
- CNET
The Next Planet Parade Takes Place at the End of August. Here's How to See It
Fresh off the excitement of the Perseids meteor shower is a chance to see six planets in the sky at the same time. These events, colloquially known as planet parades, only occur about once or twice a year, with the most recent one in February showing off all seven planets at once. The next one will feature six of our closest celestial neighbors, and the event starts on Aug. 20. The six planets sharing the sky will be Mercury, Venus, Jupiter, Saturn, Neptune and Uranus. Mars will technically be there at the beginning of the night, but it dips below the horizon right after sunset, so it won't be visible when all of the others are. Of those, Mercury, Venus and Jupiter will be visible to the naked eye, while the others will require high-powered binoculars or, preferably, a telescope. Even though they're spread out across the eastern and southern skies, the planets pair up with this one, making many of them pretty easy to find if you know what to look for. From east to west, here's where each one will be. Mercury - Eastern sky near the Cancer constellation. It'll pop over the horizon just before sunrise, so you'll have limited time to view it before the sun comes up and obfuscates it. - Eastern sky near the Cancer constellation. It'll pop over the horizon just before sunrise, so you'll have limited time to view it before the sun comes up and obfuscates it. Venus - At the lower tip of the Gemini constellation in the eastern sky, a couple of hours before sunrise. - At the lower tip of the Gemini constellation in the eastern sky, a couple of hours before sunrise. Jupiter - Will be near Venus, also in the Gemini constellation. It rises about an hour before Venus does. - Will be near Venus, also in the Gemini constellation. It rises about an hour before Venus does. Uranus - Will be near the upper tip of Taurus, rising after midnight. This one will require some magnification. If you see Pleiades, a cluster of stars at the upper tip of Taurus, you've gone too far upward. - Will be near the upper tip of Taurus, rising after midnight. This one will require some magnification. If you see Pleiades, a cluster of stars at the upper tip of Taurus, you've gone too far upward. Saturn and Neptune - These two are right next to each other and will be sitting between the Pisces and Cetus constellations in the southern skies. Neptune will be closer to Pisces while Saturn will be closer to Cetus. Since it takes a long time for planets to move through the night sky, Aug. 20 is the starting point, and it'll run through the rest of the month. Once September hits, Mercury will be too close to the sun, which will obscure it. From that point, there will be a five-planet parade for a while until Venus sinks below the horizon in early October. So, in all, you'll have a chance to see at least five planets for over a month. Will the planet parade be visible from my region? Yes. We double checked Stellarium's sky map from a variety of locations across the country, and everything above will be applicable everywhere in the continental US. Per Starwalk, the parade will also be visible in other parts of the world after the following dates for about the same amount of time (one to two weeks). Abu Dhabi - Aug. 9 - Aug. 9 Athens, Beijing, Berlin, Tokyo and London - Aug. 10 - Aug. 10 Mumbai and Hong Kong - Aug. 11 - Aug. 11 Reykjavik, São Paulo and Sydney - Aug. 12 The planets will move based on date, though. The above locations are where they'll be around Aug. 20, but if you're looking a week or so later, they'll be in the same general area, but will shift to a slightly different part of the sky. Will I need any special equipment? Yes. Neptune and Uranus, especially, will require some sort of magnification to see. We recommend a telescope, but high-powered binoculars may work if the sky is dark enough. Saturn is also difficult to see without magnification, so you'll want it for that too. Jupiter, Venus, and Mercury should be visible on their own with the naked eye. We also recommend taking a trip out to the country, as light pollution from suburbs and cities can make it even more difficult to see Neptune and Uranus. The moon will be out as well, which may make Venus, Jupiter, and Mercury harder to see. Other factors like weather may also make it more difficult to see all of them. If you're lucky, you may see a few shooting stars at the tail end of Perseids as well.
UPI
2 hours ago
- UPI
NASA seeks moon and Mars communications, navigation proposals
NASA projects the Artemis II Mission patch onto the Vehicle Assembly Building at the Kennedy Space Center in Florida on April 3 before a manned 10-day flight around the moon. File Photo by Joe Marino/UPI | License Photo July 23 (UPI) -- Planned moon and Mars missions require timely communications and navigation systems, which is prompting NASA officials to request ideas via proposals from U.S. firms. NASA on July 7 issued a request for proposals for a "high-bandwidth, high-reliability communications infrastructure" between the surfaces of the moon and Mars and respective Earth-based communications centers. "These partnerships foster important advancements in communications and navigation," said Greg Heckler, deputy program manager for NASA's Space Communications and Navigation program. "It allows our astronauts, our rovers, our spacecraft - all NASA missions - to expand humanity's exploration of the moon, Mars and beyond," Heckler said. The communications and navigation infrastructure would support a marketplace for ongoing science, exploration and economic development in space by NASA and private aerospace firms. More than 100 NASA and private space missions rely on the NASA SCAN program's Near Space and Deep Space networks, according to the space agency. Such missions support astronauts on the International Space Station, future Artemis moon missions, Earth weather monitoring, lunar exploration and researching the solar system and beyond. NASA is accepting submissions through 5 p.m. EDT on Aug. 13. The space agency in December awarded contracts for the Near Space Network to Intuit Machines of Houston; Norway's Kongsberg Satellite Services; SSC Space U.S. Inc. of Horsham, Pa.; and Viasat Inc. of Duluth, Ga. Such initiatives are intended to enable manned missions to Mars and support a moon-based habitat and lunar surface cargo lander. NASA also approved contracts with nine companies that paid each between $200,000 and $300,000 to conduct tests in support of future Mars missions. The tests involve commercial and exploration missions that are part of NASA's Mars Exploration Program, which is slated to send missions to Mars over the next two decades.
Yahoo
8 hours ago
- Yahoo
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here. A selection of key takeaways includes: The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC. Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication. The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm. Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon PattonDirector of IR & Communicationjpatton@ Investor Relations for Oncolytics Mike MoyerLifeSci Advisors+1-617-308-4306mmoyer@ Media Contact for Oncolytics Owen BlaschakLifeSci Communicationsoblaschak@ Logo - View original content to download multimedia: SOURCE Oncolytics Biotech® Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
